These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 22310247

  • 1. Diagnostic value of recombinant human thyrotropin-stimulated ¹²³I whole-body scintigraphy in the follow-up of patients with differentiated thyroid cancer.
    Alzahrani AS, AlShaikh O, Tuli M, Al-Sugair A, Alamawi R, Al-Rasheed MM.
    Clin Nucl Med; 2012 Mar; 37(3):229-34. PubMed ID: 22310247
    [Abstract] [Full Text] [Related]

  • 2. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
    Mazzaferri EL, Kloos RT.
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
    [Abstract] [Full Text] [Related]

  • 3. Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence.
    Rosario PW, Furtado Mde S, Mineiro Filho AF, Lacerda RX, Calsolari MR.
    Thyroid; 2012 Nov; 22(11):1165-9. PubMed ID: 23050784
    [Abstract] [Full Text] [Related]

  • 4. Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma.
    Robbins RJ, Tuttle RM, Sharaf RN, Larson SM, Robbins HK, Ghossein RA, Smith A, Drucker WD.
    J Clin Endocrinol Metab; 2001 Feb; 86(2):619-25. PubMed ID: 11158019
    [Abstract] [Full Text] [Related]

  • 5. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
    Rosario PW, Mineiro Filho AF, Lacerda RX, dos Santos DA, Calsolari MR.
    Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
    [Abstract] [Full Text] [Related]

  • 6. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P, Kuhn-Lansoy C, Edet-Sanson A, Hapdey S, Modzelewski R, Hitzel A, d'Anjou J, Basuyau JP.
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [Abstract] [Full Text] [Related]

  • 7. Use of the recombinant human TSH stimulated thyroglobulin level and diagnostic whole body scan in children with differentiated thyroid carcinoma.
    Hoe FM, Charron M, Moshang T.
    J Pediatr Endocrinol Metab; 2006 Jan; 19(1):25-30. PubMed ID: 16509525
    [Abstract] [Full Text] [Related]

  • 8. Role of [(18)F]-fluorodeoxy-D-glucose positron emission tomography and computed tomography in the early detection of persistent/recurrent thyroid carcinoma in intermediate-to-high risk patients following initial radioactive iodine ablation therapy.
    Kim MH, O JH, Ko SH, Bae JS, Lim DJ, Kim SH, Baek KH, Lee JM, Kang MI, Cha BY, Lee KW.
    Thyroid; 2012 Feb; 22(2):157-64. PubMed ID: 22224820
    [Abstract] [Full Text] [Related]

  • 9. Incidence and implications of negative serum thyroglobulin but positive I-131 whole-body scans in patients with well-differentiated thyroid cancer prepared with rhTSH or thyroid hormone withdrawal.
    Cherk MH, Francis P, Topliss DJ, Bailey M, Kalff V.
    Clin Endocrinol (Oxf); 2012 May; 76(5):734-40. PubMed ID: 22050475
    [Abstract] [Full Text] [Related]

  • 10. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma.
    Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, Lippi F, Taddei D, Grasso L, Pinchera A.
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3668-73. PubMed ID: 12915653
    [Abstract] [Full Text] [Related]

  • 11. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures.
    Giovanella L, Ceriani L, Ghelfo A, Keller F, Sacchi A, Maffioli M, Spriano G.
    Clin Chem Lab Med; 2006 Aug; 44(5):648-52. PubMed ID: 16681439
    [Abstract] [Full Text] [Related]

  • 12. Recombinant human thyrotropin in follow-up of patients with differentiated thyroid cancer.
    Podoba J.
    Bratisl Lek Listy; 2010 Aug; 111(1):38-40. PubMed ID: 20429310
    [Abstract] [Full Text] [Related]

  • 13. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
    Giovanella L, Ceriani L, Suriano S, Ghelfo A, Maffioli M.
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
    [Abstract] [Full Text] [Related]

  • 14. Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma.
    David A, Blotta A, Rossi R, Zatelli MC, Bondanelli M, Roti E, Braverman LE, Busutti L, degli Uberti EC.
    Thyroid; 2005 Feb; 15(2):158-64. PubMed ID: 15753676
    [Abstract] [Full Text] [Related]

  • 15. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels.
    Castagna MG, Brilli L, Pilli T, Montanaro A, Cipri C, Fioravanti C, Sestini F, Capezzone M, Pacini F.
    J Clin Endocrinol Metab; 2008 Jan; 93(1):76-81. PubMed ID: 17971424
    [Abstract] [Full Text] [Related]

  • 16. Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience.
    Giusti M, Zoccola R, Guazzini B, Molinari E, Valenti S, Villa G, Bertolazzi L, Minuto F.
    Minerva Endocrinol; 2003 Sep; 28(3):191-203. PubMed ID: 14605601
    [Abstract] [Full Text] [Related]

  • 17. Serum thyroglobulin concentrations and (131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone.
    David A, Blotta A, Bondanelli M, Rossi R, Roti E, Braverman LE, Busutti L, degli Uberti EC.
    J Nucl Med; 2001 Oct; 42(10):1470-5. PubMed ID: 11585859
    [Abstract] [Full Text] [Related]

  • 18. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer.
    Leboulleux S, Schroeder PR, Busaidy NL, Auperin A, Corone C, Jacene HA, Ewertz ME, Bournaud C, Wahl RL, Sherman SI, Ladenson PW, Schlumberger M.
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1310-6. PubMed ID: 19158200
    [Abstract] [Full Text] [Related]

  • 19. Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma.
    David A, Blotta A, Rossi R, Zatelli MC, Bondanelli M, Roti E, Braverman LE, Busutti L, degli Uberti EC.
    Thyroid; 2005 Mar; 15(3):267-73. PubMed ID: 15785246
    [Abstract] [Full Text] [Related]

  • 20. Timing of post 131I ablation diagnostic whole body scan in differentiated thyroid cancer patients. Less than four months post ablation may be too early.
    Winter M, Winter J, Heinzel A, Behrendt FF, Krohn T, Mottaghy FM, Verburg FA.
    Nuklearmedizin; 2015 Mar; 54(4):151-7. PubMed ID: 26028188
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.